Cancer immunotherapy: a new hope for patients

Cancer Facts And Figures

Cancer is the second leading cause of death globally and accounted for about 9 million deaths last year, a figure that seems to be constantly on the rise. This represents approximately one patient dying of cancer every 4 seconds.

Cancer: The Immunotherapy Revolution

Thanks to recent breakthroughs in Immuno-Oncology, some patients who would have been considered incurable just a few years ago can now gain several years of life, and sometimes even undergo complete remission.

Facing A New Challenge

Unfortunately, many patients cannot benefit from this medical revolution due to the low mutation rate of their tumor cells, rendering tumors “invisible” to their immune system.

Learn More

AbLeads: New therapies targeting incurable cancers

Personalizing Therapies

Due to the heterogeneous nature of cancer, it is not possible to rely on any given therapeutic product to eventually treat every patient. Instead, we think that future advances in Oncology will be based on personalized treatments that have the potential to harness the power of the immune system.

A New Generation Of Therapeutic Antibodies

AbLeads’ ambition is to extend the benefits of Immunotherapy to a much greater number of patients, for whom no cure is available yet. To do so, we are developing a new generation of personalized therapeutic antibodies capable of activating the immune detection of tumors with a very low mutational profile.

Our Unique Dualock Display™ Technology

To achieve this goal, our young startup has designed a unique antibody display technology allowing for the development of these innovative next-generation therapeutic antibodies bearing unprecedented specificity towards their cancer targets.

Learn More
AbLeads develops personalized antibody therapies

We Need Your Help!

Your support is vital for us. Donate today to help us develop our technology and take this fantastic project further ahead!

Help Us!

Our Partners

AbLeads Partners Bordeaux INP

Latest News

AbLeads at Biofit 2025

AbLeads wraps up a successful BioFIT 2025: strong interest in our personalized antibody development platform for cancer patients

AbLeads has just concluded a highly productive edition of BioFIT 2025 in Strasbourg, marked by insightful conferences, high-quality discussions, and promising new connections across the European biotech ecosystem. The event was a great opportunity to present AbLeads’ innovative Dualock Display™ platform, designed to enable the rapid development of personalized anti-cancer antibodies. The concept resonated strongly with attendees, and we received enthusiastic feedback from experts, investors, and potential partners.

2017 Pepite award ceremony at Poitiers

AbLeads wins best innovative startup award!

Young startup AbLeads developing personalized anti-cancer treatments has won best innovative startup award  “Prix PÉPITE” in Nouvelle-Aquitaine region (Bordeaux’s region).  This award was created 3 years ago by the French ministry for Higher Education and Research with the aim of supporting the emergence of innovative startups.

AbLeads attended Immuno-Oncology conference Meet2Win 2017

AbLeads at Meet2Win 2017!

AbLeads attended this year’s Meet2Win oncology business convention organized by MATWIN, in Bordeaux. This turned out to be a great opportunity to meet major actors of the oncology field coming from biotechs, pharmas, startups, clinics and academic institutions all over Europe.

See all our news